Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance)
- Citation:
- Blood vol 124 (21) abstr 8
- Meeting Instance:
- ASH 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2913
- Pharmas:
- Grants:
- Corr. Author:
- Guido Marcucci
- Authors:
- Guido Marcucci Susan Geyer John Zhao Andrew J Caroll Donna Bucci Geoffrey L Uy William Blum Timothy Pardee Meir Wetzler Wendy Stock Jonathan E. Kolitz Ann-Kathrin Eisfeld Clara D. Bloomfield Richard M. Stone Richard A. Larson
- Networks:
- Study
- CALGB-10801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: